Kura Oncology Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

KURA$7.57+4.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(In thousands, except par value data)

	December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$37,318	$51,802
Short-term investments	386,639	386,183
Prepaid expenses and other current assets	8,524	8,441
Total current assets	432,481	446,426
Property and equipment, net	1,859	2,540
Operating lease right-of-use assets	6,993	3,842
Other long-term assets	7,602	3,498
Total assets	$448,935	$456,306
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$33,757	$21,739
Current operating lease liabilities	1,506	2,318
Total current liabilities	35,263	24,057
Long-term debt, net	9,332	9,158
Long-term operating lease liabilities	6,362	2,548
Other long-term liabilities	705	265
Total liabilities	51,662	36,028
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding	—	—
Common stock, $0.0001 par value; 200,000 shares authorized; 74,350 and 68,314 shares issued and outstanding as of December 31, 2023 and 2022, respectively	7	7
Additional paid-in capital	1,119,976	997,111
Accumulated other comprehensive loss	(1,271)	(8,032)
Accumulated deficit	(721,439)	(568,808)
Total stockholders’ equity	397,273	420,278
Total liabilities and stockholders’ equity	$448,935	$456,306

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.